Silk Road Medical, headquartered in Sunnyvale, California, is an innovative medical device company focused on the $5 billion neurovascular device market. Silk Road’s ground-breaking technology allows faster and safer interventional access to the neurovascular system. The company’s devices enable vascular access via a puncture adjacent to the collarbone instead of the traditional approach of accessing the vascular system through the groin. Silk Road’s novel approach enables physicians to avoid routing catheters through the length of the body, thereby decreasing procedure time, improving the maneuverability of catheters, and preventing vascular debris from being dislodged. Silk Road is developing devices for two main applications: (i) carotid revascularization, a procedure to clear blockages in the arteries that supply blood to the brain, where the company successfully completed a pivotal clinical trial called ROADSTER and has submitted for FDA clearance; and (ii) interventions to treat ischemic stroke and cerebral aneurysms.
In April 2011, Warburg Pincus led a Series B financing of Silk Road. Subsequently, Warburg Pincus has continued to invest to support product development and clinical trials of the company’s technology.
Back to Previous Page